{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:02:39Z","timestamp":1784512959840,"version":"3.55.0"},"reference-count":49,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1157506"],"award-info":[{"award-number":["GNT1157506"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1196900"],"award-info":[{"award-number":["GNT1196900"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To quantify the real\u2010world use and describe characteristics of paediatric patients initiating biologic medicines for immune\u2010mediated inflammatory diseases (IMIDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dispensing claims for Australians aged less than 18\u2009years were used to examine uptake and use trends of nine biologic medicines used for the treatment of IMIDs. A 15% random sample of the population was used for dispensings between 2013 and 2017, and a 30% sample for dispensings between 2017 and 2020. Incidence and prevalence rates of use per 1\u2009000\u2009000 population per year were calculated. Patient demographics at the time of first dispensing were determined and the number of unique medicines dispensed per person across the study period was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incidence of use of biologics increased from 108 per million in 2014 to 192 per million in 2020, while prevalence increased from 352 per million to 877 per million over the same period. 1131 children were dispensed at least one biologic medicine; infliximab, adalimumab or etanercept accounted for 80% of dispensings. Mean age at first dispensing was 14\u2009years (standard deviation: 3\u2009years) and 51% were male. Of children initiated on biologics, 55% were first dispensed treatment for inflammatory bowel diseases and 29% for inflammatory arthropathies. While most children were dispensed only one unique biologic medicine, 15% were dispensed two, and 3% three or more over the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that children remain on treatment for extended periods of time and nearly one in five children were dispensed multiple biologic medicines. Post\u2010market studies should be prioritised to monitor safety among these groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70412","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:52:07Z","timestamp":1782957127000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uptake and Use of Biologic Therapies in Paediatric Immune\u2010Mediated Inflammatory Diseases: An Australian Population\u2010Based Study"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-2942","authenticated-orcid":false,"given":"Jun Ni","family":"Ho","sequence":"first","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre, College of Health Adelaide University  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Hillen","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre, College of Health Adelaide University  Adelaide Australia"},{"name":"School of Pharmacy and Pharmaceutical Sciences, Faculty of Health, Medicine and Behavioural Sciences The University of Queensland  Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Nassar","sequence":"additional","affiliation":[{"name":"Child Population and Translational Health Research, Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Charles Perkins Centre The University of Sydney  Sydney Australia"},{"name":"Leeder Centre for Health Policy, Economics and Data, Faculty of Medicine and Health The University of Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-9028","authenticated-orcid":false,"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[{"name":"Centre of Public Health Sciences, Faculty of Medicine University of Iceland  Reykjavik Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre, College of Health Adelaide University  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8617-6055","authenticated-orcid":false,"given":"Benjamin","family":"Daniels","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010021\u201000603\u20101"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909094"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology11070973"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102193"},{"key":"e_1_2_11_6_1","first-page":"565","article-title":"Inflammatory Bowel Disease in Adolescents","volume":"46","author":"Rosen M. J.","year":"2017","journal-title":"Australian Journal for General Practitioners"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010015\u20100256\u20107"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010021\u201000498\u20103"},{"key":"e_1_2_11_9_1","unstructured":"Australian Commission on Safety and Quality in Health Care (ACSQHC) NPS MedicineWise \u201cBiologics and Other Specialised Medicines \u201d(2025) https:\/\/www.nps.org.au\/bdmards."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741\u20107015\u201011\u201088"},{"key":"e_1_2_11_11_1","unstructured":"Australian Government Department of Health and Aged Care: Pharmaceutical Benefits Scheme (PBS) \u201cBiological Products and Brands listed on the Pharmaceutical Benefits Scheme \u201d(2024) https:\/\/www.pbs.gov.au\/info\/browse\/biological\u2010medicines\u2010currently\u2010listed\u2010on\u2010the\u2010pbs."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10601333.2015.1001900"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(04)17670\u20108"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107074"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231222415"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2388689"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107843"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104\u2010015\u20101616\u20108"},{"key":"e_1_2_11_19_1","unstructured":"Australian Government Department of Health and Aged CareandPharmaceutical Benefits Scheme (PBS) \u201cPBS Statistics \u201d(2025) https:\/\/www.pbs.gov.au\/info\/browse\/statistics."},{"key":"e_1_2_11_20_1","unstructured":"Australian Government Services Australia \u201cPharmaceutical Benefits Schedule Statistics \u201d(2025) https:\/\/www.servicesaustralia.gov.au\/pharmaceutical\u2010benefits\u2010schedule\u2010statistics?context=22."},{"key":"e_1_2_11_21_1","unstructured":"Australian Government Department of Health and Aged Care Pharmaceutical Benefits Scheme (PBS) \u201cDUSC Public Release Documents by Medicine\/Medicine Group \u201d(2025)https:\/\/www.pbs.gov.au\/browse\/publications."},{"key":"e_1_2_11_22_1","unstructured":"Australian Bureau of Statistics \u201c3101.0\u2014Australian Demographic Statistics 2022 September \u201d(2024)https:\/\/www.abs.gov.au\/statistics\/people\/population\/national\u2010state\u2010and\u2010territory\u2010population\/latest\u2010release."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ppe.12870"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12803"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17217"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43041"},{"key":"e_1_2_11_27_1","volume-title":"Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act","author":"Field M. J.","year":"2012"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12406"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.54"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70175"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14020188"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894\u2010020\u201000773\u20103"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.012"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13880"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23870"},{"key":"e_1_2_11_36_1","unstructured":"Therapeutic Guidelines Ltd \u201cRheumatoid Factor\u2010Negative Polyarticular Juvenile Idiopathic Arthritis \u201d(2024)https:\/\/app.tg.org.au\/viewTopic?etgAccess=true&guidelinePage=Rheumatology&topicfile=c_RHG_Rheum\u2010factor\u2010negative\u2010polyarticular\u2010jia_topic_1&guidelinename=auto&sectionId=c_RHG_Rheum\u2010factor\u2010negative\u2010polyarticular\u2010jia_topic_1#c_RHG_Rheum\u2010factor\u2010negative\u2010polyarticular\u2010jia_topic_1."},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102017\u2010212089"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075\u2010016\u20101170\u20103"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa877"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1856"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key262"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.S375890"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020165"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13166"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13601\u2010020\u201000335\u2010w"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144192"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100721"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010024\u201000653\u20106"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071068"},{"key":"e_1_2_11_50_1","unstructured":"Summary of Product Characteristics: Inflectra (infliximab) \u201cPfizer Europe MA EEIG \u201d(2013)https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/inflectra\u2010epar\u2010product\u2010information_en.pdf."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T01:42:14Z","timestamp":1784511734000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/pds.70412"],"URL":"https:\/\/doi.org\/10.1002\/pds.70412","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70412"}}